Search for “lymphoma”
Search results
-
CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL.
CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone …
-
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
… of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Journal …
-
Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada.
… Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. Journal …
-
Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
… Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma. Journal J Clin …
-
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
… parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab. …
-
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
… rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. Journal …
-
Diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma. Journal Hematol …
-
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
… and patient characteristics on survival in plasmablastic lymphoma. Journal Blood, …
-
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
… as Frontline Therapy in Older Adults With Hodgkin Lymphoma. Journal J Clin …
-
Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
… Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial. …
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.